VentriPoint Diagnostics (TSE:VPT) has released an update.
Ventripoint Diagnostics Ltd. has announced its intention to extend the offering period for its non-brokered convertible debentures by thirty days, subject to TSX Venture Exchange approval. These debentures will be convertible into common shares at a set price, and feature an automatic conversion option if share prices exceed a certain threshold. The raised capital will support Ventripoint’s operational, sales, and marketing efforts, as well as provide general working capital.
For further insights into TSE:VPT stock, check out TipRanks’ Stock Analysis page.
